Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 5Neoplasms 3Carcinoma, Renal Cell 2Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Lung Neoplasms 1Locally Advanced Rectal Adenocarcinoma 1Liposarcoma 1Leiomyosarcoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 23Nivolumab 22aldesleukin 21Cyclophosphamide 20Ipilimumab 17Interleukin-2 17fludarabine 15fludarabine phosphate 14cemiplimab 12Radiotherapy 7Fluorouracil 7Dacarbazine 6binimetinib 5Vemurafenib 5Temozolomide 5Surgical Procedures, Operative 5Sirolimus 5Radiation 5Biopsy 5Aminolevulinic Acid 5encorafenib 4dabrafenib 4Photochemotherapy 4Educational Status 4trametinib 3sonidegib 3montanide ISA 51 3avelumab 3Tacrolimus 3Sodium Chloride 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Skin Neoplasms × sotigalimab × Clear all
NCT04337931 2024-02-13

A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma

Apexigen America, Inc.

Phase 2 Terminated
45 enrolled 14 charts
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡